• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗疟药物靶向疟原虫碳酸酐酶:向青蒿琥酯杂合化合物的双重作用机制发展。

Antimalarial Agents Targeting Plasmodium falciparum Carbonic Anhydrase: Towards Artesunate Hybrid Compounds with Dual Mechanism of Action.

机构信息

Department of Pharmacy "G. d'Annunzio", University of Chieti-Pescara, 66100, Chieti, Italy.

Istituto di Bioscienze e Biorisorse CNR, 80131, Napoli, Italy.

出版信息

ChemMedChem. 2023 Nov 2;18(21):e202300267. doi: 10.1002/cmdc.202300267. Epub 2023 Sep 21.

DOI:10.1002/cmdc.202300267
PMID:37697903
Abstract

Malaria continues to be a major public health challenge worldwide and, as part of the global effort toward malaria eradication, plasmodium carbonic anhydrases (CAs) have recently been proposed as potential targets for malaria treatment. In this study, a series of eight hybrid compounds combining the Artesunate core with a sulfonamide moiety were synthesized and evaluated for their inhibition potency against the widely expressed human (h) CAs I, II and the isoform from P. falciparum (PfCA). All derivatives demonstrated high inhibition potency against PfCA, achieving a K value in the sub-nanomolar range (0.35 nM). Two Compounds showed a selectivity index of 4.1 and 3.1, respectively, against this protozoan isoform compared to hCA II. Three Derivatives showed no cytotoxic effects on human gingival fibroblasts at 50 μM with a high killing rate against both P. falciparum and P. knowlesi strains with IC in the sub-nanomolar range, providing a wide therapeutic window. Our findings suggest that these compounds may serve as promising leads for developing new antimalarial drugs and warrant further investigation, including activity against antimalarial-resistant strains, mode of action studies, and in vivo efficacy assessment in preclinical mouse models of malaria.

摘要

疟疾仍然是全球主要的公共卫生挑战之一,作为全球消除疟疾努力的一部分,疟原虫碳酸酐酶(CA)最近被提议作为疟疾治疗的潜在靶点。在这项研究中,合成了一系列 8 个将青蒿素核心与磺胺部分结合的杂合化合物,并评估了它们对广泛表达的人(h)CA I、II 和来自疟原虫(PfCA)的同工酶的抑制效力。所有衍生物对 PfCA 均表现出高抑制效力,达到亚纳摩尔范围的 K 值(0.35 nM)。与 hCA II 相比,两种化合物对这种原生动物同工酶的选择性指数分别为 4.1 和 3.1。三种衍生物在 50 μM 时对人牙龈成纤维细胞没有细胞毒性作用,对疟原虫和伯氏疟原虫株均具有高杀伤率,IC 值在亚纳摩尔范围内,提供了较宽的治疗窗。我们的研究结果表明,这些化合物可能成为开发新抗疟药物的有前途的先导化合物,值得进一步研究,包括对抗疟药物耐药株的活性、作用机制研究以及在疟疾临床前小鼠模型中的体内疗效评估。

相似文献

1
Antimalarial Agents Targeting Plasmodium falciparum Carbonic Anhydrase: Towards Artesunate Hybrid Compounds with Dual Mechanism of Action.抗疟药物靶向疟原虫碳酸酐酶:向青蒿琥酯杂合化合物的双重作用机制发展。
ChemMedChem. 2023 Nov 2;18(21):e202300267. doi: 10.1002/cmdc.202300267. Epub 2023 Sep 21.
2
Malaria parasite carbonic anhydrase: inhibition of aromatic/heterocyclic sulfonamides and its therapeutic potential.疟原虫碳酸酐酶:芳香族/杂环磺酰胺类药物的抑制作用及其治疗潜力
Asian Pac J Trop Biomed. 2011 Jun;1(3):233-42. doi: 10.1016/S2221-1691(11)60034-8.
3
Investigating the antiplasmodial activity of primary sulfonamide compounds identified in open source malaria data.研究在开源疟疾数据中鉴定出的伯胺类化合物的抗疟活性。
Int J Parasitol Drugs Drug Resist. 2017 Apr;7(1):61-70. doi: 10.1016/j.ijpddr.2017.01.003. Epub 2017 Jan 13.
4
Carbonic anhydrase inhibitors: inhibition of Plasmodium falciparum carbonic anhydrase with aromatic/heterocyclic sulfonamides-in vitro and in vivo studies.碳酸酐酶抑制剂:芳香族/杂环磺胺类药物对恶性疟原虫碳酸酐酶的抑制作用——体外和体内研究
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5466-71. doi: 10.1016/j.bmcl.2008.09.030. Epub 2008 Sep 11.
5
Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy.恶性疟原虫碳酸酐酶是疟疾化疗的一个可能靶点。
J Enzyme Inhib Med Chem. 2004 Jun;19(3):249-56. doi: 10.1080/14756360410001689577.
6
Isolation and structure elucidation of a steroidal moiety from and evaluation of antimalarial efficacy against artemisinin resistance kelch 13 protein.从 和 中分离并阐明甾体部分,并评估其对青蒿素耐药性 kelch 13 蛋白的抗疟疗效。
J Biomol Struct Dyn. 2023 Jul;41(11):4993-5006. doi: 10.1080/07391102.2022.2077448. Epub 2022 May 18.
7
The alpha-carbonic anhydrase from the malaria parasite and its inhibition.疟原虫的α-碳酸酐酶及其抑制作用。
Curr Pharm Des. 2008;14(7):631-40. doi: 10.2174/138161208783877901.
8
Sulfonamide inhibition studies of the η-class carbonic anhydrase from the malaria pathogen Plasmodium falciparum.对疟疾病原体恶性疟原虫的η类碳酸酐酶的磺胺抑制研究。
Bioorg Med Chem. 2015 Feb 1;23(3):526-31. doi: 10.1016/j.bmc.2014.12.009. Epub 2014 Dec 11.
9
Investigation of new ferrocenyl-artesunate derivatives as antiparasitics.新型二茂铁基青蒿琥酯衍生物作为抗寄生虫药物的研究。
Dalton Trans. 2023 Nov 7;52(43):15786-15797. doi: 10.1039/d3dt02254d.
10
Antiplasmodial profile of selected compounds from Malaria Box: in vitro evaluation, speed of action and drug combination studies.《疟疾盒中选定化合物的抗疟谱:体外评价、作用速度和药物组合研究》
Malar J. 2019 Dec 30;18(1):447. doi: 10.1186/s12936-019-3069-3.

引用本文的文献

1
Design and Synthesis of Ketoconazole Derivatives as Innovative Anti-Infective Agents.酮康唑衍生物作为新型抗感染药物的设计与合成
Arch Pharm (Weinheim). 2025 Jul;358(7):e70062. doi: 10.1002/ardp.70062.
2
Dual inhibition of carbonic anhydrases VA and VII by silychristin and isosilybin A from Silybum marianum: A potential antiobesity strategy.水飞蓟宾和异水飞蓟宾A对水飞蓟中碳酸酐酶VA和VII的双重抑制作用:一种潜在的抗肥胖策略。
Arch Pharm (Weinheim). 2025 Mar;358(3):e2400966. doi: 10.1002/ardp.202400966.
3
Lasamide, a Potent Human Carbonic Anhydrase Inhibitor from the Market: Inhibition Profiling and Crystallographic Studies.
拉沙米胺,一种来自市场的强效人碳酸酐酶抑制剂:抑制谱分析与晶体学研究。
ACS Med Chem Lett. 2024 Sep 30;15(10):1749-1755. doi: 10.1021/acsmedchemlett.4c00341. eCollection 2024 Oct 10.
4
Lasamide Containing Sulfonylpiperazines as Effective Agents for the Management of Glaucoma Associated Symptoms.含有磺酰哌嗪的拉沙米德作为治疗青光眼相关症状的有效药物。
ChemMedChem. 2024 Dec 16;19(24):e202400601. doi: 10.1002/cmdc.202400601. Epub 2024 Nov 8.
5
Benzenesulfonamide decorated dihydropyrimidin(thi)ones: carbonic anhydrase profiling and antiproliferative activity.苯磺酰胺修饰的二氢嘧啶(硫)酮:碳酸酐酶分析及抗增殖活性
RSC Med Chem. 2024 Mar 26;15(6):1929-1941. doi: 10.1039/d4md00101j. eCollection 2024 Jun 19.